VERNON HILLS, Ill.--(BUSINESS WIRE)--Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, announced today that Jeffrey Bernstein, President and CEO, and Barry Hollingsworth, CFO will present at the RBC Capital Markets 2014 Healthcare Conference on Wednesday, February 26 at 4:05pm Central time at the New York Palace in New York City.
About Elorac, Inc.
Elorac, Inc. is a privately owned, specialty pharmaceutical company engaged in the development and commercialization of novel products for dermatology, allergy and oncology. The Company markets dermatological products in the United States through its own dedicated sales force. Elorac has a robust pipeline of products in development, including naloxone lotion for treatment of pruritus accompanying cutaneous T-cell lymphoma, a product that has received orphan drug and fast-track designations from the U.S. Food and Drug Administration, and cidoxepin, the most potent histamine antagonist ever discovered for chronic urticaria. According to Inc. magazine’s 2013 list of fastest-growing private U.S. companies, Elorac ranked 23rd among health-care companies and No. 1 among pharmaceutical companies.